Mingyuan Medicare Announces Collaboration with CHGC and SBC
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
The Board of Mingyuan Medicare Development Company Limited announces that the Company had entered into a milestone co-operation agreement (the "Co-operation Agreement") with Chinese National Human Genome Centre in Shanghai (CHGC) and Shanghai Biochip Company Limited (SBC) on the joint establishment of a dynamic technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases on demand basis.
The two products above are able to qualitatively detect new Influenza A/H1N1 virus, seasonal Influenza A H1 virus and Non-A H1 Influenza virus and identify with fluorescent labels, being applicable to respiratory tract sample test (nasopharynx swab / aspirate or nasal cavity wash / aspirate).
The diagnostic kits are able to detect Influenza A viruses at a very early stage of infection. As the test result is available in 2 hours, the kits can be used in hospitals, border checkpoints and clinics to help diagnose suspected symptomatic and asymptomatic infections and thus effectively prevent the virus from further spreading.
Mr. Henry Chien, CEO of Mingyuan Medicare, said, "We are honoured to be a partner of CHGC and SBC. The technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases is believed to play an important role in the development of human health. Currently, Influenza A viruses (including the recent outbreak of Influenza A (H1N1) virus) is a highly infectious disease which has long been regarded as a major health hazard to human. Furthermore, the World Health Organization may soon raise the influenza pandemic alert level from Phase 5 to Phase 6, the highest pandemic phase. The two newly-developed advanced diagnostic kits for detecting Influenza A viruses help to identify Human Swine Flu (A H1N1) patients, and this is believed to be critical to effectively preventing the spread of the infectious disease and to improve the chance of recovery."
The two products above are able to qualitatively detect new Influenza A/H1N1 virus, seasonal Influenza A H1 virus and Non-A H1 Influenza virus and identify with fluorescent labels, being applicable to respiratory tract sample test (nasopharynx swab / aspirate or nasal cavity wash / aspirate).
The diagnostic kits are able to detect Influenza A viruses at a very early stage of infection. As the test result is available in 2 hours, the kits can be used in hospitals, border checkpoints and clinics to help diagnose suspected symptomatic and asymptomatic infections and thus effectively prevent the virus from further spreading.
Mr. Henry Chien, CEO of Mingyuan Medicare, said, "We are honoured to be a partner of CHGC and SBC. The technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases is believed to play an important role in the development of human health. Currently, Influenza A viruses (including the recent outbreak of Influenza A (H1N1) virus) is a highly infectious disease which has long been regarded as a major health hazard to human. Furthermore, the World Health Organization may soon raise the influenza pandemic alert level from Phase 5 to Phase 6, the highest pandemic phase. The two newly-developed advanced diagnostic kits for detecting Influenza A viruses help to identify Human Swine Flu (A H1N1) patients, and this is believed to be critical to effectively preventing the spread of the infectious disease and to improve the chance of recovery."
